Table 3.

Risk of BCR after prostatectomy in 368 prostate cancer cases at different lengths of follow-up associated with PAH-DNA adduct levels in prostate cells adjusting for clinical risk factors

Cell type	Follow-up period
Model variable	1 y	18 mo	2 y	3 y
	HR (95% CI)	HR (95% CI)	HR (95% CI)	HR (95% CI)
Tumor adduct level
2nd Quartile	1.79 (0.49–6.52)	1.06 (0.42–2.67)	0.99 (0.42–2.34)	0.79 (0.36–1.76)
3rd Quartile	3.43 (1.09–10.77)	1.71 (0.75–3.90)	1.54 (0.71–3.34)	1.37 (0.68–2.74)
4th Quartile	3.05 (0.82–11.38)	1.31 (0.47–3.61)	1.39 (0.56–3.46)	1.12 (0.49–2.54)
Linear trend	1.50 (1.04–2.17)	1.17 (0.87–1.57)	1.17 (0.88–1.54)	1.10 (0.86–1.42)
Above median	2.41 (1.10–5.29)	1.52 (0.80–2.87)	1.48 (0.82–2.70)	1.41 (0.82–2.43)
Nontumor adduct level
2nd Quartile	1.29 (0.31–5.35)	0.96 (0.32–2.84)	0.89 (0.33–2.40)	0.80 (0.34–1.91)
3rd Quartile	3.83 (1.20–12.27)	3.15 (1.32–7.48)	2.66 (1.20–5.91)	1.89 (0.92–3.92)
4th Quartile	3.45 (1.04–11.43)	1.82 (0.69–4.82)	1.77 (0.73–4.27)	1.50 (0.69–3.28)
Linear trend	1.57 (1.11–2.22)	1.34 (1.01–1.78)	1.32 (1.01–1.71)	1.23 (0.96–1.57)
Above median	3.24 (1.41–7.42)	2.56 (1.32–4.99)	2.35 (1.27–4.34)	1.89 (1.09–3.28)
No. events	28	40	46	55

NOTE: Clinical risk factors include PSA, tumor grade, and tumor stage.